Loading
Life sciences · Journal article
International Journal of Innovative Technologies in Social Science · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
One of the most widespread liver diseases in the world is metabolic dysfunction-associated steatotic liver disease (MASLD), known until recently as non-alcoholic fatty liver disease (NAFLD). Its prevalence is estimated at 25% in the global population. MASLD is defined as a clinical condition characterized by excessive fat accumulation in the liver in the presence of at least one cardiometabolic risk factor. Although obesity plays a significant role in the pathomechanism of MASLD, it is estimated that approximately 10-20% of MASLD cases occur in individuals with a BMI <25 kg/m² (<23 kg/m² in the Asian population). As studies show, individuals with lean MASLD have a higher risk of liver fibrosis and overall mortality. The aim of this study is a critical review of the current literature regarding the Lean MASLD phenotype, with particular emphasis on its metabolic heterogeneity. The work analyzes unique pathophysiological mechanisms, such as genetic predispositions and adipose tissue distribution disorders, and evaluates their impact on the risk of progression to advanced fibrosis and hepatocellular carcinoma. This work constitutes a literature review, focusing on clinical and cohort studies as well as review papers concerning the pathogenesis, diagnostics, and clinical course of liver steatosis in individuals with a normal BMI. The literature analysis indicates a significant role of genetic variants, mainly the PNPLA3 polymorphism (I148M), which predisposes lean individuals to disease progression independently of metabolic factors. It has been shown that despite a normal BMI, these patients are often characterized by visceral adipose tissue dysfunction and an altered gut microbiota profile. Metabolic heterogeneity is manifested by the existence of a subgroup of patients with a "metabolically healthy" profile, in whom cardiovascular risk may be lower, but the risk of progression of liver lesions remains significant. The following work emphasizes that Lean MASLD is not a milder form of liver steatosis, and its diagnostics require going beyond the standard BMI measurement. It is necessary to implement personalized monitoring strategies, taking into account the genetic profile and metabolic assessment, to prevent long-term complications in this specific group of patients.